Otwarty dostęp

Classification of Gastroenteropancreatic Neuroendocrine Tumors


1. Amin MB., Edge SB, Greene FL et al., editors. AJCC cancer staging manual, 8th ed.; 2017:351-419.10.1007/978-3-319-40618-3 Search in Google Scholar

2. Wang Y, Wang W, Jin K, Fang C, Lin Y, Xue L et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide longacting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13(3):1165-74.10.3892/ol.2017.5591540348628454229 Search in Google Scholar

3. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, et al. Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117:3332-41.10.1002/cncr.2585521246527 Search in Google Scholar

4. Klöppel G, Couvelard A, Hurban RH. Neoplasms of the neuroendocrinae pancreas in WHO classification of tumors of endocrine organs, 4th ed., IARC, 2017; 211-4. Search in Google Scholar

5. Kruljac I, Pape UF. The classification of neuroendocrine neoplasms: „Neuroendocrine carcinomas“ revisited – a 2017 update and future perspectives. Endocr Oncol Metab. 2017;3(2): 37-42. Search in Google Scholar

6. Perren A, Couvelard A, Scoazec J, Costa F, Borbath I, Delle Fave G et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology. 2017;105(3):196-200.10.1159/00045795628190015 Search in Google Scholar

7. Bosman F, Carneiro F, Hruban R, Theise N: WHO classification of tumors of the digestive system, 4 ed. Lyon: IARC Press; 2010. Search in Google Scholar

8. Capelli P, Fassan M, Scarpa A Pathology – grading and staging of GEP-NET. Best Pract Res Clin Gastroenterol. 2012;26(6):705-17.10.1016/j.bpg.2013.01.00323582914 Search in Google Scholar

9. Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):68-81.10.1093/annonc/mdv50526487581 Search in Google Scholar

10. Dias AR, Azevedo BC, Alban LBV, Yagi OK, Ramos MFKP, Jacob CE et al. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig. 2017;30(2):150-4.10.1590/0102-6720201700020016554379729257854 Search in Google Scholar

11. Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11-6.10.1016/j.anndiagpath.2017.04.00528807335 Search in Google Scholar

12. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinol. 2012;95(2):98-119.10.1159/000335591370144922261919 Search in Google Scholar

13. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179(4068):77-9.10.1126/science.179.4068.774682131 Search in Google Scholar

14. Kiviniemi A, Gardberg M, Kivinen K, Posti JP, Vuorinen V, Sipilä J, et al. Somatostatin receptor 2A in gliomas: association with oligodendrogliomas and favourable outcome. Oncotarget. 2017;8(30):49123-32.10.18632/oncotarget.17097556475428467778 Search in Google Scholar

15. Öberg K and Lamberts SWJ. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer. 2016; 23(12):R551-R566.10.1530/ERC-16-015127697899 Search in Google Scholar

16. Herac M, Niederle B, Raderer M, Krebs M, Kaserer K, Koperek O. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. APMIS. 2016;124:839-45.10.1111/apm.1258427539746 Search in Google Scholar

17. Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas. 2016;45(10):1386-93.10.1097/MPA.0000000000000700506797227622342 Search in Google Scholar

18. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V et al Gastrinoma (duodenal and pancreatic). Neuroendocrinol. 2006;84(3):173-82.10.1159/000098009 Search in Google Scholar

19. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199-203.10.1126/science.1200609314449621252315 Search in Google Scholar

20. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115-54.10.1007/s12022-022-09708-235294740 Search in Google Scholar

21. Fang JM, Shi J. A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification. Arch Pathol Lab Med. 2019;143(11):1317-26.10.5858/arpa.2019-0338-RA714176031509453 Search in Google Scholar

22. Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther. 2018;18(9):837-60.10.1080/14737140.2018.1496822628341029973077 Search in Google Scholar

23. La Rosa S, Uccella S. Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord. 2021;22(3):527-38.10.1007/s11154-020-09612-2834645133169199 Search in Google Scholar

24. Li MX, Wang HY, Yuan CH, Ma CL, Jiang B, Li L,et al. The eighth version of American Joint Committee on Cancer nodal classification for high grade pancreatic neuroendocrine tumor should be generalized for the whole population with this disease. Medicine (Baltimore). 2020;99(37):e22089.10.1097/MD.0000000000022089748959732925749 Search in Google Scholar

25. Oka N, Kasajima A, Konukiewitz B, Sakurada A, Okada Y, Kameya T, et al. Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms. Neuroendocrinol. 2020;110(5):393-403.10.1159/00050277631422400 Search in Google Scholar

26. Păun I, Becheanu G, Costin AI, Constantin VD, Mihai GM, Radu L, et al. Aspects regarding nomenclature, classification and pathology of neuroendocrine neoplasms of the digestive system - a review. Rom J Morphol Embryol. 2018;59(3):673-78. Search in Google Scholar

27. Inzani F, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin North Am. 2018;47(3):463-70.10.1016/j.ecl.2018.04.00830098710 Search in Google Scholar

Częstotliwość wydawania:
2 razy w roku
Dziedziny czasopisma:
Medicine, Clinical Medicine, other, Ophthalmology, Public Health, Pharmacy, Clinical Pharmacy